The New Dawn

In the inaugural episode of The Quantum Leap, Dr. Nirdosh Jagota presents a strategic and forward-looking examination of the AI-native pharmaceutical enterprise—a fundamental departure from the traditional drug development model. Drawing on over three decades of global experience in biotechnology and regulatory leadership, Dr. Jagota analyzes the structural limitations of the current R&D paradigm, including escalating development costs, extended timelines, and high clinical attrition rates.

This episode introduces the defining pillars of the AI-native organization: data as a core asset, end-to-end AI platforms, and automated closed-loop laboratories. Through case studies involving industry leaders such as Eli Lilly, Novartis, Insilico Medicine, Recursion, and Exscientia, Dr. Jagota explores how integrated data architectures, machine learning-driven discovery engines, and robotics-enabled experimentation are reshaping the economics and physics of drug development.

He further evaluates the strategic responses of established pharmaceutical companies—builders, network orchestrators, and enterprise optimizers—highlighting the competitive necessity of AI adoption across the value chain.

This foundational discussion establishes the conceptual framework for the series, offering a rigorous perspective on how AI is transforming not only scientific workflows but also business models, talent requirements, and investment strategies within the life sciences sector.

For extended analysis, publications, and Dr. Jagota’s broader thought leadership, please visit: 🌐 https://nirdoshjagota.us/

🌐 https://nirdoshjagota.net/

🌐 https://nirdoshjagota.com/

🌐 https://aboutnirdoshjagota.com/